ProCE Banner Activity

HOVON-65/GMMG-HD4: Long-term Results for Bortezomib-Based Therapy in NDMM

Slideset Download
Conference Coverage
Long-term bortezomib-based therapy improves survival, including patients with del(17p) or renal impairment.

Released: December 07, 2015

Expiration: December 05, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen